ORIGINAL RESEARCH

Prognostic impact of preoperatively elevated and postoperatively normalized carcinoembryonic antigen levels following curative resection of stage I-III rectal cancer

Yuya Nakamura | Dai Shida | Taro Tanabe | Yasuyuki Takamizawa | Jun Imaizumi | Yuka Ahiko | Ryohei Sakamoto | Konosuke Moritani | Shunsuke Tsukamoto | Yukihide Kanemitsu

Department of Colorectal Surgery, National Cancer Center Hospital, Tokyo, Japan

Correspondence
Dai Shida, 5-1-1 Tsukiji, Chuo-ku, Tokyo 1040045, Japan.
Email: dshida@ncc.go.jp

Abstract

Background: Preoperative and early postoperative serum carcinoembryonic antigen (CEA) levels are known prognostic factors in rectal cancer. Recently, a large-scale study on colon cancer revealed that “preoperatively elevated and postoperatively normalized CEA levels” is not an indicator of poor prognosis. However, whether this holds true in rectal cancer patients is unknown. This study aimed to investigate the prognostic significance of preoperatively elevated and postoperatively normalized CEA levels in rectal cancer patients undergoing curative resection.

Methods: Subjects were consecutive stage I-III rectal cancer patients who underwent curative resection without preoperative treatment at National Cancer Center Hospital between 2000 and 2015. Overall survival (OS) and the hazard function of recurrence or death were analyzed according to the CEA levels, as follows: normal preoperative CEA (normal group), preoperatively elevated but postoperatively normalized CEA (normalized group), and preoperatively and postoperatively elevated CEA (elevated group).

Results: The normalized group (n = 235) had worse OS (HR 1.49, 95% CI 1.08-2.04; P = .0142) compared to the normal group (n = 1208), and better OS compared to the elevated group (n = 47) (HR 0.53, 95% CI 0.31-0.91; P = .0208). The elevated group had the highest and earliest peak in hazard function, followed by the normalized group and the normal group, with median times to recurrence of 8.8, 15.5, and 18.5 months, respectively (P = .0223).

Conclusions: Prognosis after resection of rectal cancer was worse in patients with preoperatively elevated and postoperatively normalized CEA compared to those with normal preoperative CEA. Patients with elevated preoperative CEA might require intensive follow-up even if levels normalize after resection, especially in earlier periods, for early detection of recurrence.
INTRODUCTION

Guidelines of the National Comprehensive Cancer Network (NCCN), European Society for Medical Oncology (ESMO), and American Society of Clinical Oncology (ASCO) recommend preoperative workup and postoperative measurements of serum carcinoembryonic antigen (CEA) every 3-6 months for patients with rectal cancer who undergo curative resection.1-3 Both preoperative and early postoperative CEA levels are known to be prognostic factors after curative resection for rectal cancer, with elevated preoperative CEA3-5 as well as continuously elevated postoperative CEA being associated with worse survival.6-8

In a recent study, recurrence-free survival (RFS) of patients with postoperatively normalized CEA was shown to be similar to that of patients with normal preoperative CEA,9 suggesting that perioperative change in CEA, rather than preoperative level of CEA, is important in predicting prognosis in colon cancer. Meanwhile, rectal cancer differs from colon cancer in terms of survival and recurrence patterns,10 and thus, changes in CEA levels after curative resection might also differ.8 In this regard, the prognostic significance of preoperatively elevated but postoperatively normalized CEA in rectal cancer warrants further investigation.

Preoperative treatment such as chemoradiotherapy and chemotherapy prior to total mesorectal excision is the current standard for locally advanced rectal cancer in many Western countries.11 Meanwhile, in Japan, upfront surgery (total mesorectal excision plus lateral lymph node (LN) dissection) without any preoperative therapy is performed as the standard treatment for rectal cancer.12 This unique strategy in Japan allows for serial evaluation of perioperative CEA levels in patients with rectal cancer, without any influence of preoperative therapy.

This study aimed to investigate the prognostic impact of preoperative and early postoperative serum CEA in patients with stage I-III rectal cancer who underwent curative resection, focusing mainly on the prognostic significance of preoperatively elevated and postoperatively normalized CEA following curative resection.

MATERIALS AND METHODS

Study population and design

The study population comprised patients with stage I-III rectal adenocarcinoma who underwent curative resection at National Cancer Center Hospital in Japan from January 2000 to December 2015. According to the Japanese classification of colorectal, appendiceal, and anal carcinoma, the rectum is defined as the segment from the height of the inferior border of the second sacral vertebra to the superior border of the puborectal sling.13 Patients who underwent preoperative treatment such as chemoradiotherapy or chemotherapy were excluded, given the possible influence on preoperative serum CEA. Patients with elevated preoperative CEA, for whom early postoperative CEA measurements were not available, were also excluded from the analysis.

Preoperative CEA was defined as CEA measured immediately prior to surgery, and early postoperative CEA was defined as CEA measured within 3 months after surgery and before adjuvant chemotherapy. The reference range of CEA was set at ≤5 ng/ml. Patients were divided into the following three groups according to levels of preoperative and early postoperative CEA: normal preoperative CEA (normal group), elevated preoperative and normalized postoperative CEA (normalized group), and elevated preoperative and postoperative CEA (elevated group). RFS and overall survival (OS) were investigated in each group.

The Institutional Review Board (IRB) of the National Cancer Center Hospital approved this retrospective study (IRB code: 2017-437).

Follow-up

Postoperative follow-up consisted of serum CEA and CA19-9 measurements every 3 months for the first 2 years, then every 6 months for 3 years; computed tomography (CT) every 6 months for 5 years; and colonoscopy in the first and third year, as described previously.14 Follow-up data were documented prospectively until an event occurred, or until the study cutoff date of August 2018.

Statistical analysis

Pearson’s Chi-square test and the Kruskal-Wallis test were performed for categorical variables and continuous variables, respectively, to examine various factors in each group. Continuous variables are presented as median (interquartile range). RFS was defined as the interval between the date of surgery of primary cancer and the date of recurrence or death from all causes. OS was defined as the interval between the date of surgery of primary cancer and the date of death from all causes. Patients alive at the end of the follow-up period were censored. The Kaplan-Meier method

KEYWORDS
carcinoembryonic antigen, postoperative CEA, preoperative CEA, prognostic factor, rectal cancer
was used to estimate RFS and OS. Differences in survival were assessed with the log-rank test. Multivariable Cox proportional hazards regression models were subsequently fitted to evaluate factors independently associated with recurrence and death. Selection of covariates to be included in the multivariable analysis was performed based on information from previous studies. The hazard function (smoothed hazard estimate) of recurrence or death, which conveys the instantaneous conditional recurrence or death rate at time $t$, was also analyzed and expressed as the number of events per unit of time (months). Propensity score matching analysis was conducted in order to balance the distribution of covariates between the normal preoperative CEA group and elevated preoperative CEA group (which included the normalized and elevated subgroups), as described previously. Multivariable logistic regression was used to generate propensity score-predicting preoperative CEA status based on confounding covariates, including sex (male vs female), procedure (sphincter-preserving vs non-preserving), lymphatic invasion (present vs absent), venous invasion (present vs absent), and TNM stage (I/II vs III). Propensity scores were used for matching, which pair patients with normal preoperative CEA and patients with elevated preoperative CEA according to similarities in their baseline characteristics. Each patient with normal preoperative CEA was matched 1:1 with a patient with elevated preoperative CEA using the closest estimated propensity on the logit scale within a specified range (smaller than 0.05 of estimated logits as the caliper width) in order to reduce differences between the two groups, and outcomes in matched patients were compared and analyzed.

$P < .05$ was considered statistically significant, and 95% confidence intervals (CIs) were calculated. Bonferroni correction for multiple comparisons was performed to compare outcomes. All statistical analyses were performed using the JMP14 software program (SAS Institute Japan Ltd., Tokyo, Japan) or R version 3.5.3 (R Project).

## RESULTS

### 3.1 Study cohort characteristics

Figure 1 shows the flowchart of patient selection and classification into three groups according to levels of preoperative and postoperative CEA. A total of 1661 stage I-III rectal cancer patients who underwent curative resection were identified. Of these, 1490 patients were subjected to analysis, excluding 45 who underwent preoperative chemoradiotherapy or chemotherapy, and 126 with elevated preoperative CEA, for whom early postoperative CEA measurements were not available. Data on preoperative CEA were obtained from all patients; 1208 had normal preoperative CEA, 235 had elevated preoperative CEA which subsequently normalized postoperatively, and 47 had elevated preoperative CEA which persisted postoperatively.

Table 1 summarizes patient clinicopathologic features by group. Patients with elevated postoperative CEA (elevated group) were older ($P = .0016$) and had poor tumor differentiation ($P = .002$), and those with elevated preoperative CEA (both the normalized and elevated groups) had more venous invasion ($P < .0001$) and advanced tumor stage ($P < .0001$). The tumor distance from the anal verge was longer in the normal group ($P = .0197$), and sphincter-preserving surgery was performed more frequently in the normalized group ($P < .0001$).

Fourteen patients received postoperative radiation. Of these, seven had positive CRM, three had lateral LN metastases, and four underwent transanal resection. Twelve patients had normal preoperative CEA levels and two had elevated preoperative but normalized postoperative CEA levels.

### 3.2 Long-term outcomes after curative resection

Figure 2A,B show RFS and OS curves by group ($P < .0001$ and $P < .0001$, respectively). The 5-year RFS and 5-year OS rates were 78.0% and 90.7%, respectively, for the normal group (n = 1208), 65.1% and 80.5%, respectively, for the normalized group (n = 235), and 49.6% and 61.1%, respectively, for the elevated group (n = 47).

Bonferroni correction for multiple comparisons revealed a worse RFS in the normalized group compared to the normal group ($P < .0001$), and no significant difference in RFS between the normalized group and elevated group ($P = .0721$). Moreover, the normalized group had a worse OS than the normal group ($P = .0001$), but a better OS than the elevated group ($P = .0016$).

### 3.3 Hazard functions for disease recurrence

Figure 2C shows hazard function curves by group. These curves represent the instantaneous risk for the event at each time-point, whereas Kaplan-Meier survival curves represent the cumulative risk. The elevated group had the highest and earliest peak in hazard function (peak rate: 0.023, peak months: 0), followed by the normalized group (peak rate: 0.011, peak months: 4.6) and the normal group (peak rate: 0.0054, peak months: 8.1). The median time to recurrence from operation was shortest for the elevated group at 8.8 months, followed by the normalized group.
(15.5 months) and the normal group (18.5 months) (Table 3; \(P = .0223\)).

### 3.4 Stage-specific long-term outcomes after curative resection

The 5-year OS rate was 95.5% (95% CI 93.2-97.0) for 564 stage I patients, 90.2% (95% CI 86.1-93.1) for 313 stage II patients, and 79.4% (95% CI 75.9%-82.6%) for 613 stage III patients (Table 2).

Among stage III patients, stage-specific RFS and OS rates significantly differed by group (RFS: HR 1.52, 95% CI 1.14-2.03 for normalized vs normal groups (\(P = .0042\)) and HR 2.38, 95% CI 1.47-3.87 for elevated vs normal groups (\(P = .0004\)) and HR 1.39, 95% CI 1.03-2.13 for stage I vs stage II (\(P = .0249\))). On the other hand, among stage I/II patients, both stage-specific RFS and OS rates showed no significant differences by group (Figure S1).

### 3.5 Factors affecting prognosis after curative resection

In terms of RFS, univariable analysis revealed that age (\(\geq 65\) years; \(P = .0012\)), sex (male; \(P = .0014\)), tumor distance from the anal verge (\(\leq 5\) cm; \(P = .0013\)), tumor differentiation (moderate or poor; \(P < .0001\)), lymphatic invasion (present; \(P < .0001\)), venous invasion (present; \(P < .0001\)), TNM stage (stage II or III; \(P < .0001\)), circumferential resection margin (positive; \(P < .0001\)), and adjuvant chemotherapy (present; \(P < .0001\)) were significantly associated with recurrence. Multivariable analyses using Cox proportional hazards regression models revealed that older age (HR 1.47, 95% CI 1.19-1.80; \(P = .0033\)), male (HR 1.45, 95% CI 1.16-1.83; \(P = .0014\)), tumor distance from the anal verge \(\leq 5\) cm (HR 1.36, 95% CI 1.11-1.66; \(P = .0026\)), presence of lymphatic invasion (HR 1.69, 95% CI 1.36-2.09; \(P < .0001\)), presence of venous invasion (HR 1.34, 95% CI 1.07-1.69; \(P = .0127\)), retrieved LNs \(< 12\) (HR 1.66, 95% CI 1.13-2.45; \(P = .0096\)), advanced TNM stage (stage II vs stage I: HR 2.11, 95% CI 1.50-2.99; \(P < .0001\), and stage III vs stage I: HR 3.91, 95% CI 2.81-5.45; \(P < .0001\)), and positive circumferential resection margin (HR 2.01, 95% CI 1.34-3.00; \(P = .0007\)) were independent predictors of recurrence (Supplementary Table).

In terms of overall survival, univariable analysis revealed that age (\(\geq 65\) years; \(P < .0001\)), operation year (2000-2007; \(P = .0006\)), sex (male; \(P = .0021\)), tumor distance from the anal verge (\(\leq 5\) cm; \(P = .0284\)), tumor differentiation (moderate or poor; \(P < .0001\)), lymphatic invasion (present; \(P < .0001\)), venous invasion (present; \(P < .0001\)), TNM stage (stage II or III; \(P < .0001\)), and adjuvant chemotherapy (present; \(P = .0074\)) were significantly associated with worse OS. Multivariable analyses using Cox proportional hazards...
| TABLE 1  Patient characteristics                                                                 |
|------------------------------------------------------------------------------------------------|
| All                                               | Normal CEA (N = 1208) | Normalized CEA (N = 235) | Elevated CEA (N = 47) | P value |
| Age (years; median, IQR)                          | 62 (54, 69)           | 62 (54, 68)               | 68 (59, 73)            | .0016   |
| Operation year                                     | .992                  |
| 2000-2007                                         | 816 (55)              | 662 (55)                  | 128 (54)               | 26 (55)  |
| 2008-2015                                         | 674 (45)              | 546 (45)                  | 107 (46)               | 21 (45)  |
| Sex                                               | .647                  |
| Male                                              | 1001 (67)             | 806 (67)                  | 161 (69)               | 34 (72)  |
| Female                                            | 489 (33)              | 402 (33)                  | 74 (31)                | 13 (28)  |
| Tumor distance from the anal verge, cm            | .0197                 |
| ≤5                                                | 670 (45)              | 523 (43)                  | 125 (53)               | 22 (53)  |
| >5                                                | 820 (55)              | 685 (57)                  | 110 (47)               | 25 (47)  |
| Clinical stage                                    | <.0001                |
| I                                                 | 544 (37)              | 518 (43)                  | 18 (8)                 | 8 (17)   |
| II                                                | 392 (26)              | 302 (25)                  | 71 (30)                | 19 (40)  |
| III                                               | 554 (37)              | 388 (32)                  | 146 (62)               | 20 (43)  |
| Operative procedure                               | <.0001                |
| Sphincter-preserving                              | 1246 (84)             | 1040 (86)                 | 168 (71)               | 38 (81)  |
| Non-preserving                                    | 244 (16)              | 168 (14)                  | 67 (29)                | 9 (19)   |
| Tumor differentiation                             | .0015                 |
| Well                                              | 803 (54)              | 681 (56)                  | 98 (42)                | 24 (51)  |
| Moderate                                          | 615 (41)              | 472 (39)                  | 125 (53)               | 18 (38)  |
| Poor                                              | 71 (4)                | 54 (4)                    | 12 (5)                 | 5 (11)   |
| Not available                                     | 1 (0.07)              | 1 (0.08)                  | 0                      | 0        |
| Lymphatic invasion                                | .1204                 |
| Yes                                               | 457 (30)              | 352 (29)                  | 87 (37)                | 18 (38)  |
| No                                                | 1028 (69)             | 852 (70)                  | 147 (62)               | 29 (62)  |
| Not available                                     | 5 (0.34)              | 4 (0.33)                  | 1 (0.43)               | 0        |
| Venous invasion                                   | <.0001                |
| Yes                                               | 828 (55)              | 626 (52)                  | 166 (71)               | 36 (77)  |
| No                                                | 656 (44)              | 576 (47)                  | 69 (29)                | 11 (23)  |
| Not available                                     | 6 (0.40)              | 6 (0.50)                  | 0                      | 0        |
| No. of retrieved LNs, median (IQR)                | 28 (19, 41)           | 26 (18, 39)               | 38 (26, 52)            | 30 (21, 43) | <.0001 |
| T category                                        | <.0001                |
| T1                                                | 355 (24)              | 347 (28)                  | 6 (2)                  | 2 (4)    |
| T2                                                | 375 (25)              | 338 (28)                  | 30 (13)                | 7 (15)   |
| T3                                                | 690 (46)              | 480 (40)                  | 176 (75)               | 34 (72)  |
| T4                                                | 70 (5)                | 43 (4)                    | 23 (10)                | 4 (9)    |
| N category                                        | <.0001                |
| N0                                                | 877 (59)              | 771 (64)                  | 86 (37)                | 20 (43)  |
| N1                                                | 377 (25)              | 283 (23)                  | 79 (34)                | 15 (32)  |
| N2                                                | 236 (16)              | 154 (13)                  | 70 (30)                | 12 (25)  |
| TNM stage (UICC 8th)                              | <.0001                |

(Continues)
regression models revealed that older age (HR 1.95, 95% CI 1.50-2.54; \( P < .0001 \)), early phase of operation year (2000-2007 vs 2008-2015: HR 1.67, 95% CI 1.21-2.29; \( P = .0017 \)), male (HR 1.57, 95% CI 1.16-2.13; \( P = .0033 \)), moderate or poor differentiation (moderate vs well: HR 1.32, 95% CI 1.00-1.74; \( P = .0479 \), and poor vs well: HR 1.71, 95% CI 1.06-2.77; \( P = .0276 \)), presence of lymphatic invasion (HR 1.71, 95% CI 1.06-2.77; \( P = .0276 \)), and positive circumferential resection margin (HR 1.59, 95% CI 1.20-2.09; \( P = .0010 \)), advanced tumor stage (stage II vs stage I: HR 1.78, 95% CI 1.14-2.80; \( P = .0118 \), and stage III vs stage I: HR 3.11, 95% CI 2.04-4.74; \( P < .0001 \)), and positive circumferential resection margin (HR 1.79, 95% CI 1.03-3.12; \( P = .0400 \)) were all independent predictors of worse OS (Table 2). After adjusting for these clinical factors, the normalized group had worse OS (HR 1.45, 95% CI 1.06-2.00; \( P = .0211 \)) compared to the normal group, but better OS compared to the elevated group (HR 0.55, 95% CI 0.32-0.95; \( P = .0305 \)) (Table 2).

### 3.6 Recurrence patterns by group

During the study period, 315 (21%) patients developed recurrence. The recurrence rates were 6% (35/564) for stage I patients, 19% (58/313) for stage II patients, and 36% (222/613) for stage III patients.

According to CEA levels, recurrence rates were 18% (222/1208) for the normal group, 33% (77/235) for the normalized group, and 34% (16/47) for the elevated group (Table 3), suggesting that patients with elevated preoperative CEA (either with normalized or elevated postoperative CEA) are more prone to recurrence (\( P < .0001 \)).

Overall local recurrence rate was 5.4% (80/1490). According to CEA levels, 5% (58/1208) in the normal group, 7% (17/235) in the normalized group, and 11% (5/47) in the elevated group developed local recurrence (\( P = .0844 \)).

### 3.7 Propensity score matching

Propensity score matching analysis was conducted to balance the distribution of covariates between the normal preoperative CEA group and elevated preoperative CEA group (which includes the normalized and elevated subgroups). After propensity score matching, 280 matched pairs of patients were selected and patient distributions were balanced between the two groups. In the cohort of matched patients (n = 560), the elevated preoperative CEA group had worse OS than the normal preoperative CEA group (\( P = .0024 \)). Specifically, the 5-year OS for normal and elevated preoperative CEA groups was 86.7% and 77.2%, respectively.

### 4 DISCUSSION

We demonstrated that in stage I-III rectal cancer patients who underwent no preoperative therapy, those with preoperatively elevated and postoperatively normalized CEA following resection of rectal cancer had worse prognoses, both in terms of RFS and OS, compared to those with normal preoperative CEA. These findings are quite different from a previous report of a large-scale study on colon cancer,\(^9\) which concluded that preoperatively elevated and postoperatively normalized CEA levels is not an indicator of poor prognosis. In contrast, we found that “preoperatively elevated and postoperatively normalized CEA levels” may be a specific indicator of poor prognosis in rectal cancer.
cancer patients. Thus, the prognostic significance of CEA levels following curative resection of rectal cancer differs from that of colon cancer. On the other hand, our finding that the prognoses of patients with preoperatively elevated and postoperatively normalized CEA were better than those of patients with continuously elevated perioperative CEA is consistent with a previous report. Moreover, those with elevated postoperative CEA had the highest and earliest peak in hazard function, with a significantly shorter median time to recurrence, followed by those with normalized postoperative CEA, and those with normal preoperative CEA, in this order. Meanwhile, recurrence sites showed no significant differences among the three groups. Taken together, our results suggest that patients with elevated preoperative CEA are at high risk of developing early recurrence, both distant and local, after resection of rectal cancer, regardless of whether levels normalize postoperatively or not.

Controversies exist regarding the survival benefits of intensive follow-up after curative resection of colorectal cancer. In rectal cancer alone, several studies have shown that intensive monitoring is beneficial in terms of detecting treatable residual disease such as local recurrence. The results of the present study suggest that patients with rectal cancer showing elevated preoperative CEA may require different surveillance from patients with normal preoperative CEA. Intensive follow-up might allow for detection of treatable residual disease, thereby improving patient outcomes.

In the present study, stage-specific RFS and OS rates in patients with stage III rectal cancer, but not stage I or II rectal cancer, differed significantly by group, similar to the previous report. One possible reason for this is the inclusion of patients with falsely elevated CEA in stage I/II,

![FIGURE 2](image_url)

Recurrence-free survival curves (A) and overall survival curves (B) for the normal group (normal preoperative CEA), normalized group (elevated preoperative and normalized postoperative CEA), and elevated group (elevated preoperative and postoperative CEA). C, Hazard function curves for each group, indicating the instantaneous conditional recurrence or death at time \( t \).
due to the reference range of CEA ≤ 5 ng/ml used in the present study. Indeed, among patients with preoperatively elevated CEA (either with postoperatively normalized or elevated CEA; n = 282), median levels of preoperative CEA were 7.4 ng/ml and 9.7 ng/ml in stage I (n = 39) and II (n = 72) patients, respectively, compared to 12.2 ng/ml in stage III (n = 173) patients (P = .0037) (data not shown). Thus, stage I/II patients had lower levels of preoperative

| TABLE 2 Univariable and multivariable analyses of overall survival |
| --- |
| **No. of patients** | **5-year OS** | **95% CI** | **P** | **HR** | **95% CI** | **P** |
| **Age, y** | | | | | | |
| <65 | 906 | 90.2 | 88.0-92.0 | <.0001 | Reference |
| ≥65 | 584 | 83.6 | 80.2-86.6 | <.0001 | 1.95 | 1.50-2.54 | <.0001 |
| **Operation year** | | | | | | |
| 2000-2007 | 816 | 85.4 | 82.8-87.7 | .0006 | 1.67 | 1.21-2.29 | .0017 |
| 2008-2015 | 674 | 91.0 | 88.2-93.1 | Reference |
| **Sex** | | | | | | |
| male | 1001 | 86.0 | 83.5-88.1 | .0021 | 1.57 | 1.16-2.13 | .0033 |
| female | 489 | 91.3 | 88.2-93.6 | Reference |
| **Tumor distance from the anal verge, cm** | | | | | | |
| ≤5 | 670 | 85.9 | 82.9-88.5 | .0284 | 1.23 | 0.952-1.59 | .1125 |
| >5 | 820 | 89.0 | 86.5-91.0 | Reference |
| **Tumor differentiation** | | | | | | |
| well | 803 | 91.7 | 89.5-93.5 | <.0001 | Reference |
| moderate | 615 | 84.7 | 81.5-87.5 | 1.32 | 1.00-1.74 | .0479 |
| poor | 71 | 66.6 | 53.5-77.5 | 1.71 | 1.06-2.77 | .0276 |
| **Lymphatic invasion** | | | | | | |
| yes | 457 | 80.7 | 76.7-84.2 | <.0001 | 1.59 | 1.20-2.09 | .0010 |
| no | 1028 | 90.8 | 88.8-92.5 | Reference |
| **Venous invasion** | | | | | | |
| yes | 828 | 84.0 | 81.2-86.5 | .0001 | 1.27 | 0.954-1.70 | .1012 |
| no | 656 | 92.1 | 89.7-94.0 | Reference |
| **No. of retrieved LNs** | | | | | | |
| ≥12 | 1380 | 87.6 | 85.6-89.3 | .815 | Reference |
| <12 | 110 | 89.4 | 81.9-94.0 | 1.46 | 0.904-2.37 | .1215 |
| **TNM stage (UICC 8th)** | | | | | | |
| I | 564 | 95.5 | 93.2-97.0 | <.0001 | Reference |
| II | 313 | 90.2 | 86.1-93.1 | 1.78 | 1.14-2.80 | .0118 |
| III | 613 | 79.4 | 75.9-82.6 | 3.11 | 2.04-4.74 | <.0001 |
| **Circumferential resection margin** | | | | | | |
| Negative | 1438 | 88.2 | 86.3-90.0 | .0015 | Reference |
| Positive | 52 | 73.5 | 58.8-84.4 | 1.79 | 1.03-3.12 | .0400 |
| **Adjuvant chemotherapy** | | | | | | |
| yes | 367 | 83.0 | 78.6-86.7 | .0074 | 0.786 | 0.565-1.09 | .1529 |
| no | 1123 | 89.2 | 87.1-91.0 | Reference |
| **CEA group** | | | | | | |
| normal | 1208 | 90.7 | 88.1-91.7 | <.0001 | Reference |
| normalized | 235 | 80.5 | 74.5-85.3 | 1.45 | 1.06-2.00 | .0211 |
| elevated | 47 | 61.1 | 45.4-74.7 | 2.64 | 1.62-4.29 | <.0001 |

Abbreviations: OS: overall survival, CI: confidence interval, HR: hazard ratio, LN: lymph node, CEA: carcinoembryonic antigen.
CEA compared to stage III patients. We analyzed the outcomes using a cutoff CEA level of 10 ng/ml, but results were similar (Figure S2).

The concept of evaluating both preoperative and postoperative CEA levels, which we adopted in this study, might be beneficial in other situations. Recently, several studies have shown that CEA after preoperative chemoradiotherapy is associated with histologic response and prognosis in patients with rectal cancer.26-28 Those studies suggested that, when combined, pre- and post-chemoradiotherapy CEA could be useful as prognostic factors for disease-free survival in patients with rectal cancer who undergo treatment with neoadjuvant chemoradiotherapy and curative resection.26-28 Elevated CEA before preoperative therapy, as well as normalized CEA after preoperative therapy, may also have a specific prognostic impact.

We also analyzed the prognostic significance of serum CA19-9 levels. Among the 1490 patients of this study cohort, 1472 had information available on preoperative and early postoperative CA19-9 levels. Similar to the results for CEA, the normalized group had worse OS (n = 103; 5-year OS 72.7%) compared to the normal group (n = 1350; 5-year OS 90.7%) and better OS compared to the elevated group (n = 75; 5-year OS 59.9%) (P < .0001) (data not shown), suggesting that normalized CA19-9 after surgery may also be a specific prognostic indicator.

Our study has some limitations. First, although our large-scale study cohort was comprised of prospectively collected series of consecutive patients, the study was retrospective in nature and thus may have had selection bias. Second, this study may not directly reflect clinical practice in many Western countries, where neoadjuvant therapy is the current treatment standard. As described above, several studies in Western countries have investigated CEA changes before and after neoadjuvant therapy.26-28 However, without the knowledge of perioperative CEA changes in rectal cancer in patients who have not undergone preoperative therapy, the results of these studies cannot be fully understood. In this regard, the present study offers important insights for research studies in Japan as well as Western countries, since we examined baseline changes in perioperative CEA in rectal cancer patients without the influence of preoperative therapy. Third, confounders of CEA, such as smoking, liver disease, and diabetes, were not included in our data for analysis, although they might have resulted in false-positive CEA elevation. Fourth, due to the observational retrospective design, the timing for early postoperative CEA measurement was not consistent across patients. The half-life of CEA is 3-5 days, and serum CEA levels decrease to normal levels from 2 weeks to 1 month. Previous studies also showed considerable variation in the timing of early postoperative CEA measurements (7 days to 1 year after surgery).6,7,29-31 In this study, we focused on “early” postoperative CEA and used measurements obtained within 3 months. This period, however, might not have been long enough for recovery from postoperative complications to occur prior to initiation of adjuvant chemotherapy. Fifth, postoperative CEA measurements were not available in 126 patients, who were subsequently excluded from the analysis, and for this reason, generalizing our findings might not be feasible. Nonetheless, our findings regarding perioperative changes in CEA in rectal cancer patients of the largest cohort to date warrant further consideration.

5 CONCLUSION

Patients with elevated preoperative and normalized postoperative CEA following resection of rectal cancer had worse prognoses compared to those with normal preoperative CEA. Unlike previous reports on colon cancer, perioperative changes in CEA might also have a certain prognostic impact in addition to those of preoperative and postoperative CEA. Moreover, patients with elevated preoperative CEA might require intensive follow-up, especially in earlier periods, regardless of whether levels normalize postoperatively or not, in order to ensure early detection of recurrence after resection.

ACKNOWLEDGMENTS

The authors thank all colleagues and nurses who provided patient care.

CONFLICT OF INTEREST

None declared.

AUTHOR CONTRIBUTIONS

YN designed the study, collected the data, analyzed and interpreted the data, and prepared the manuscript. DS participated in the design and coordination of the study, analyzed and interpreted the data, and was responsible for writing the manuscript. TT, YT, JI, YA, RS, KM, ST, and YK collected the data, performed the treatments, interpreted the data, and edited the manuscript. All authors read and approved the final manuscript.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID

Dai Shida https://orcid.org/0000-0003-3294-1924

REFERENCES

1. Benson AB, Venook AP, Al-Hawary MM, et al. Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018;16:874-901.
2. Glynne-Jones R, Wyrwicz L, Tiret E, et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv22-iv40.
3. Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006;24:5313-5327.

4. Tarantino I, Warschkow R, Worni M, et al. Elevated preoperative CEA is associated with worse survival in stage I-III rectal cancer patients. Br J Cancer. 2012;107:266-274.

5. Park YJ, Youk EG, Choi HS, et al. Experience of 1446 rectal cancer patients in Korea and analysis of prognostic factors. Int J Colorectal Dis. 1999;14:101-106.

6. Lin J-K, Lin C-C, Yang S-H, et al. Early postoperative CEA level is a better prognostic indicator than is preoperative CEA level in predicting prognosis of patients with curable colorectal cancer. Int J Colorectal Dis. 2011;26:1135-1141.

7. Park YA, Lee KY, Kim NK, Baik SH, Sohn SK, Cho CW. Prognostic effect of perioperative change of serum carcinoembryonic antigen level: a useful tool for detection of systemic recurrence in rectal cancer. Ann Surg Oncol. 2006;13:645-650.

8. Steele G, Ellenberg S, Ramming K, et al. Monitoring among patients in multi-institutional adjuvant G.I. therapy protocols. Ann Surg. 1982;196:162-169.

9. Konishi T, Shimada Y, Hsu M, et al. Association of Preoperative and Postoperative Serum Carcinoembryonic Antigen and Colon Cancer Outcome. JAMA Oncol. 2018;4:309-315.

10. Park YJ, Park KJ, Park JG, Lee KU, Choek KJ, Kim JP. Prognostic factors in 2230 Korean colorectal cancer patients: analysis of consecutively operated cases. World J Surg. 1999;23:721-726.

11. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731-1740.

12. Watanabe T, Muro K, Ajioka Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. Int J Clin Oncol. 2018;23:1-34.

13. JSCCR. Japanese Classification of colorectal, appendiceal, and anal carcinoma, 3rd English edn. Tokyo: Kanehara & Co., Ltd; 2019.

14. Shida D, Ochiai H, Tsukamoto S, Kanemitsu Y. Long-term outcomes of laparoscopic versus open D3 dissection for stage II/III colon cancer: Results of propensity score analyses. Eur J Surg Oncol. 2018;44:1025-1030.

15. Compton CC, Fielding LP, Burgart LJ, et al. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000;124:979-994.

16. Hess KR, Levin VA. Getting more out of survival data by using the hazard function. Clin Cancer Res. 2014;20:1404-1409.

17. Hess KR, Serachitopol DM, Brown BW. Hazard function estimators: a simulation study. Stat Med. 1999;18:3075-3088.

18. Shida D, Tanabe T, Boku N, et al. Prognostic value of primary tumor sidedness for unresectable stage IV colorectal cancer: a retrospective study. Ann Surg Oncol. 2019;26:1358-1365.

19. Shida D, Boku N, Tanabe T, et al. Primary tumor resection for stage IV colorectal cancer in the era of targeted chemotherapy. J Gastrointest Surg. 2018.

20. Mokhles S, Macbeth F, Farewell V, et al. Meta-analysis of colorectal cancer follow-up after potentially curative resection. Br J Surg. 2016;103:1259-1268.

21. Primrose JN, Perera R, Gray A, et al. Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA. 2014;311:263-270.

22. Rosati G, Ambrosini G, Barni S, et al. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinoma. Ann Oncol. 2016;27:274-280.

23. Verbervne CJ, Zhan Z, van den Heuvel ER, et al. Survival analysis of the CEAwatch multicentre clustered randomized trial. Br J Surg. 2017;104:1069-1077.

24. Pietra N, Sarli L, Costi R, Ouchemi C, Grattarola M, Peracchia A. Role of follow-up in management of local recurrences of colorectal cancer: a prospective, randomized study. Dis Colon Rectum. 1998;41:1127-1133.

25. Rodriguez-Moranta F, Saló J, Arcusa A, et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. J Clin Oncol. 2006;24:386-393.

26. Jang NY, Kang S-B, Kim D-W, et al. The role of carcinoembryonic antigen after neoadjuvant chemoradiotherapy in patients with rectal cancer. Dis Colon Rectum. 2011;54:245-252.

27. Kim CW, Yu CS, Yang S-S, et al. Clinical significance of pre- to post-chemoradiotherapy s-CEA reduction ratio in rectal cancer patients treated with preoperative chemoradiotherapy and curative resection. Ann Surg Oncol. 2011;18:3271-3277.

28. Perez RO, Sáu Julião GP, Habr-Gama A, et al. The role of carcinoembriogenic antigen in predicting response and survival to neoadjuvant chemoradiotherapy for distal rectal cancer. Dis Colon Rectum. 2009;52:1137-1143.

29. Hotta T, Takifuji K, Yokoyama S, et al. Impact of the post/preoperative serum CEA ratio on the survival of patients with rectal cancer. Surg Today. 2014;44:2106-2115.

30. Kim JY, Kim NK, Sohn SK, et al. Prognostic value of postoperative CEA clearance in rectal cancer patients with high preoperative CEA levels. Ann Surg Oncol. 2009;16:2771-2778.

31. Yang KM, Park JJ, Kim CW, Roh SA, Cho DH, Kim JC. The prognostic significance and treatment modality for elevated pre- and postoperative serum CEA in colorectal cancer patients. Ann Surg Treat Res. 2016;91:165-171.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Nakamura Y, Shida D, Tanabe T, et al. Prognostic impact of preoperatively elevated and postoperatively normalized carcinoembryonic antigen levels following curative resection of stage I-III rectal cancer. Cancer Med. 2020;9:653–662. https://doi.org/10.1002/cam4.2758